← Leaderboards
Karl E Griswold
Dartmouth College
$6,310,128
Attributed
$8,311,126
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2009–21$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,311,126 · 10
By mechanism
R01$4,649,869 · 2
R42$1,478,414 · 1
R21$1,331,198 · 3
P20$851,645 · 4
Top collaborators
- Chris Bailey-Kellogg8 shared
- Anne Searls De Groot2 shared
Most similar at Dartmouth College
Same institution · by research overlap
- Ambrose L. Cheung$20,671,358
- Chris Bailey-Kellogg$4,233,280
- Karen A Skorupski$5,046,695
- William J Belden$1,661,025
- Sharon Elizabeth Bickel$6,606,592
Others in their field
Top investigators on “Engineering”
- David Heimbrook · Leidos Biomedical Research, Inc.$265,348,415
- Francis L Halzen · University Of Wisconsin-Madison$239,306,664
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Daniel Stanzione · Arizona State University$173,674,275
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$173,157,760
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
Research focus
EngineeringMolecularEnzymesBiological Response Modifier TherapyExhibitsBacterial InfectionsNext GenerationBaseAnti-Bacterial AgentsLifeImmunogenicityCytolysisImmune ResponseDrug ResistanceInfectionLyta EnzymeGenus StaphylococcusIn VitroLibrariesAntibioticsFutureAntibiotic ResistanceCombinatorialBacteria
Grant awards (21)
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics$547,683
R01 · FY2021 · AI · contact PI
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics$547,683
R01 · FY2020 · AI · contact PI
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics$547,683
R01 · FY2019 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2019 · GM
Design and Development of Immunotolerant S. aureus Biotherapies$609,888
R42 · FY2018 · AI
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics$547,683
R01 · FY2018 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2018 · GM
Design and Development of Immunotolerant S. aureus Biotherapies$868,526
R42 · FY2017 · AI
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics$537,153
R01 · FY2017 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2017 · GM
Engineer bifunctional antibacterial enzymes for treatment of S. aureus infections$162,000
R21 · FY2017 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2016 · GM
Engineer bifunctional antibacterial enzymes for treatment of S. aureus infections$283,500
R21 · FY2016 · AI · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$238,613
R21 · FY2013 · AI
Molecular Engineering of Humanized Anti-Staphlococcal Lytic Enzymes$237,000
R21 · FY2012 · AI · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$212,585
R21 · FY2012 · AI
COBRE P3: HUMANIZING ALGINATE DEPOLYMERASE$259,538
P20 · FY2011 · RR · contact PI
Molecular Engineering of Humanized Anti-Staphlococcal Lytic Enzymes$197,500
R21 · FY2011 · AI · contact PI
ASSESSING SYNERGIES OF ANTIBACTERIAL PROTEINS AGAINST P AERUGINOSA BIOFILMS$59,407
P20 · FY2011 · RR · contact PI
COBRE P3: HUMANIZING ALGINATE DEPOLYMERASE$265,258
P20 · FY2010 · RR · contact PI
COBRE P3: HUMANIZING ALGINATE DEPOLYMERASE$267,442
P20 · FY2009 · RR · contact PI